Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: james who wrote (1364)	12/5/1997 12:34:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 4676

James: You have a good point on this one. >>Is topical AS delivery practical? I don't know. If ISIP is successful in that, its shr will command high premiun.<< I think that they are. Highly polar and hydrophilic they are able to penetrate under the skin by diffusion. mz

To: james who wrote (1364)	12/5/1997 1:03:00 AM
From: marc ultra	Read Replies (1) \| Respond to of 4676

Keep in mind bad cases of psoriasis often treated systemically with methotrexate. Additionally psoriasis often associated with psoriatic arthritis which can be severe. Obviously they need to define their patient groups carefully to make for clean analysis. Also recently PUVA therapy (psoralen and UV-A light has been called into question due to an apparent increase in malignancies. I would guess their patient population will be severe psoriasis that's been refractory to current treatments though I don't know this. Marc